Repositioning Candidate Details
| Candidate ID: | R0139 |
| Source ID: | DB00493 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cefotaxime |
| Synonyms: | |
| Molecular Formula: | C16H17N5O7S2 |
| SMILES: | [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O |
| Structure: |
|
| DrugBank Description: | Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis). |
| CAS Number: | 63527-52-6 |
| Molecular Weight: | 455.465 |
| DrugBank Indication: | Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery. |
| DrugBank Pharmacology: | Cefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against <i>Pseudomonas aeruginosa</i>. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives. |
| DrugBank MoA: | The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III. |
| Targets: | Penicillin-binding protein 1b; Penicillin-binding protein 2a; Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 2B; Solute carrier family 22 member 6; Solute carrier family 22 member 8; Solute carrier family 22 member 11; Solute carrier family 22 member 7; Solute carrier family 15 member 1; Serum albumin; Beta-lactamase; Solute carrier family 15 member 2 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |